Selective metabolic regulations by p53 mutant variants in pancreatic cancer Authors: Sabrina Caporali, Alessio Butera, Alessia Ruzza, Carlotta Zampieri, Marina Bantula’, Sandra Scharsich, Anna-Katerina Ückert, Ivana Celardo, Ian U Kouzel, Luigi Leanza, Andreas Gruber, Joan Montero, Angelo D’Alessandro, Thomas Brunner, Marcel Leist, Ivano Amelio Published: 2024 ABSTRACT AbstractBackgroundApproximately half of all human cancers harbour mutations in the p53 gene, leading to the generation of neomorphic p53 mutant proteins. These mutants can exert gain-of-function (GOF) effects, potentially promoting tumour progression. However, the clinical significance of p53 GOF mutations, as well as the selectivity of individual variants, remains controversial and unclear.MethodsTo elucidate the metabolic regulations and molecular underpinnings associated with the specific p53R270H and p53R172H mutant variants (the mouse equivalents of human p53R273H and p53R175H, respectively), we employed a comprehensive approach. This included integrating global metabolomic analysis with epigenomic and transcriptomic profiling in mouse pancreatic cancer cells. Additionally, we assessed metabolic parameters such as oxygen consumption rate and conducted analyses of proliferation and cell–cell competition to validate the biological impact of metabolic changes on pancreatic ductal adenocarcinoma (PDAC) phenotype. Our findings were further corroborated through analysis of clinical datasets from human cancer cohorts.ResultsOur investigation revealed that the p53R270H variant, but not p53R172H, sustains mitochondrial function and energy production while also influencing cellular antioxidant capacity. Conversely, p53R172H, while not affecting mitochondrial metabolism, attenuates the activation of pro-tumorigenic metabolic pathways such as the urea cycle. Thus, the two variants selectively control different metabolic pathways in pancreatic cancer cells. Mechanistically, p53R270H induces alterations in the expression of genes associated with oxidative stress and reduction in mitochondrial respiration. In contrast, p53R172H specifically impacts the expression levels of enzymes involved in the urea metabolism. However, our analysis of cell proliferation and cell competition suggested that the expression of either p53R270H or p53R172H does not influence confer any selective advantage to this cellular model in vitro. Furthermore, assessment of mitochondrial priming indicated that the p53R270H-driven mitochondrial effect does not alter cytochrome c release or the apoptotic propensity of pancreatic cancer cells.ConclusionsOur study elucidates the mutant-specific impact of p53R270H and p53R172H on metabolism of PDAC cancer cells, highlighting the need to shift from viewing p53 mutant variants as a homogeneous group of entities to a systematic assessment of each specific p53 mutant protein. Moreover, our finding underscores the importance of further exploring the significance of p53 mutant proteins using models that more accurately reflect tumor ecology.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13046-024-03232-3.Keywords: Tumour suppressor, Gain-of-function, Cancer Metabolism, Anti-oxidant capacity Introduction P53, a critical tumour suppressor transcription factor encoded by the TP53 gene, plays a pivotal role in safeguarding genome integrity [1, 2]. Its functional significance lies in orchestrating cellular responses, including cell cycle arrest, DNA repair, apoptosis, or senescence, thereby determining the fate of cells in the face of diverse stress conditions [1, 3, 4]. Beyond its fundamental role in genome maintenance, p53 emerges as a central regulator of cellular metabolism, impacting key processes such as glucose, lipid, and nucleotide metabolism, as well as mitochondrial oxidative respiration. This multilayer control underscores p53 ability to regulate cellular fate [5, 6]. Approximately 50% of human cancers exhibit p53 inactivation, with the majority of cancer-associated p53 mutations being predominantly missense. These mutations typically cluster within hot-spot regions of the DNA-binding domain (DBD), resulting in the generation of neomorphic p53 mutant proteins [7]. Notably, these GOF mutants have been implicated in promoting tumorigenesis by enhancing glycolysis, lipid synthesis, and serine metabolism [6, 8]. Furthermore, they exert influence over the microenvironment, shaping it in a manner that significantly impacts the tumorigenic potential of cancer cells [9–11]. However, the significance of the p53 mutant GOF has been also questioned by observation that depletion of p53 mutant proteins does not affect proliferation and cell death of several cancer cell lines [12]. These highlight the complexity of p53 mutations and shift attention over the possibility that they exhibit strong context-dependent behaviour [11]. Mutations within the TP53 gene are frequently observed in pancreatic adenocarcinoma (PDAC), a globally pervasive and highly lethal malignancy characterized by an ominous prognosis and a 5-year survival rate below 10% [13, 14]. Specifically, the p53R273H variant (whose mouse orthologue is the p53R270H) is among the most frequent p53 mutations, followed by p53R175H variant (whose mouse orthologue is the p53R172H) observed in PDAC [15]. The ability of PDAC cells to grow in hostile conditions is supported by an extensive metabolic reprogramming [16], a well-established cancer hallmark, which is indispensable to help to sustain cancer cell survival and growth under microenvironmental stress conditions. Generally, the rewiring of metabolic pathways is a consequence of the activation of oncogenic signals and inactivation of tumour suppressor genes, including p53 [5, 17]. Despite the insights on the consequence of the loss of wild type p53 on cell metabolism, the impact of mutant p53 variants on the metabolic processes of pancreatic cancer remains not well understood, and the potential implications of these regulatory alterations in tumorigenesis are not fully elucidated. In this study, we employed an integrative approach, combining global metabolomics, epigenomics, and transcriptomics with functional mitochondrial studies. Our findings reveal that the mutant p53 variants, R270H and R172H, exert very specific and selective effects on distinct metabolic pathways. While p53R270H influences the mitochondrial tricarboxylic acid (TCA) cycle and glutathione metabolism, p53R172H leads to an unexpected attenuation of the urea cycle metabolism, with potential tumour-suppressive implications. At the molecular level, p53R270H and p53R172H also exert specific and selective transcriptional and epigenetic effects. p53R270H promotes the regulation of genes implicated in maintaining physiological mitochondrial fitness. In contrast, p53R172H influences the expression of enzymes involved in urea cycle metabolism. Thus, we identify potential novel gain-of-function selective mechanisms of different p53 mutant variants on cell metabolism. These results emphasize the importance of conducting a thorough evaluation tailored to the specific mutation, context, and characteristics of p53 GOF mutants in order to comprehensively explore their clinical potential. Results p53R270H, but not p53R172H, affects tricarboxylic acid cycle and mitochondrial metabolism Metabolic reprogramming in cancer provides substrates to support cell proliferation, migration, invasion and survival capabilities at different stages of carcinogenesis [18]. We selected PDAC cell line derived from pdx1-CRE mouse models with pancreas-specific expression of constitutively active KRAS (LSL-KRASG12D) and the mutation p53R270H (named KPCR270H) or p53R172H (named KPCR172H). To identify the metabolic changes associated to the p53R270H and p53R172H mutant variants, we performed a global metabolomic analysis in KPCR270H and KPCR172H proficient- and deficient- pancreatic cancer cells. The level of several metabolites belonging to nucleotides, amino acids and energy metabolism pathways were significantly affected by depletion of both variants underlying an effective impact of this neomorphic proteins on cellular processes (Fig. 1A, Supp. Fig. 1A). Integration of both datasets, however, indicated that only 7 metabolites are changing toward the same direction in both genotypes (Fig. 1B), thus mutant p53 variants associated metabolome emerge to be highly specific. Metabolic profile of p53 mutant variants in pancreatic cancer. A Volcano Plot of differentially modulated metabolites related to all biological pathways upon p53R270H depletion in KPCR270H cells (right plot) or p53R172H depletion in KPCR172H cells (left plot). B Venn diagram indicates no significant overlap between p53R270H- and p53R172H-dependent metabolomes. C Modulated metabolic pathways related to p53R270H depletion. D Heat maps representing deregulated metabolites belonging to TCA cycle and GSH Metabolism upon p53R270H depletion in KPCR270H cells. E, F Box-plots of all significantly up- or down-regulated metabolites upon mutant depletion in KPCR270H cells. Metabolites abundancies are represented as signal intensities (AU: Arbitrary Units). P-values= * p < 0.05; ** p < 0.01. Metabolomic analysis was performed on 5 biological replicates for each condition. G Seahorse mitochondrial flux analysis performed in KPCR270H and p53-depleted KPCR270H cells after 72h of silencing. Measurements were performed following injection of oligomycin (complex V inhibitor, 1 μM), FCCP (protonophore, 1.5 μM) or a mix of rotenone (complex I inhibitor, 0.5 μM) and antimycin (complex III inhibitor, 0.5 μM) to analyse respectively ATP generation, maximal respiratory capacity, and spare capacity. OCR was quantified by normalizing to the number of H-33342 positive cells. P -values= * p < 0.05; ** p < 0.01. N= 3 ± SEM KPCR270H metabolome revealed significant decrease in levels of tricarboxylic acid cycle (TCA) intermediates, such as citrate, succinate, fumarate and malate, suggesting an effect of the mutant p53R270H on mitochondrial metabolism and consequent ATP level (Fig. 1C-F). Moreover, our metabolomic analysis identified also deregulations in the glutathione (GSH) metabolic pathway (Fig. 1D, F). We observed significant reduction in PDAC cells depleted of p53R270H of 5-oxoproline, ascorbate and dehydroascorbate, compounds involved in the redox homeostasis [19]. The balance of antioxidant levels is a key aspect for cancer cell. Reactive oxygen species (ROS) accumulation is frequently occurring in cancer cells as a consequence of mitochondrial dysfunctions. To corroborate our metabolomic analysis indicating impairment of mitochondrial fitness, next we tested mitochondria function by measuring the oxygen consumption rate (OCR) with a Seahorse stress test. Under basal conditions, p53R270H-depleted KPC cells displayed a reduced OCR compared to KPC-expressing p53R270H (Fig. 1G). Following addition of carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), that uncouples oxygen consumption from ATP-synthesis, we could not detect any major increase in OCR to a maximum level suggesting a general low spare capacity in our KPC cell line. Nevertheless, we revealed a significant general reduction in the rate of maximal respiration in p53R270H depleted cells (Fig. 1G, Supp. Fig. 1C). To comprehensively assess mitochondrial fitness, we measured mitochondrial membrane potential using JC-1 staining followed by FACS analysis. Silencing of p53R270H altered mitochondrial membrane potential, showing an increase in the J-aggregate signal, which we interpreted as indicative of stressed mitochondrial activity (Supp. Fig. 1B). Our data indicate a functional link between mutant p53R270H, mitochondrial metabolism, GSH homeostasis and general mitochondrial fitness that could influence cancer cell fate [20]. Reliance on oxidative phosphorylation has been reported to be a key metabolic feature of Ras-driven PDAC stem-like cells that leads to tumour recurrence [21–23], our data however indicate a link between mutant p53R270H and these metabolic processes of possible relevance for pancreatic cancer biology. p53R172H affects the urea cycle While p53R172H did not influence TCA cycle and anti-oxidant metabolism, the top 25-enriched metabolites influenced by this p53 mutant variant appeared to belong to arginine and proline metabolism, aspartate metabolism, ammonia recycling and urea cycle (Fig. 2A-E). Urea cycle has recently emerged as a critical metabolic process for cancer cells [24]. Furthermore, wild-type p53 prevents ureagenesis and influences ammonia metabolism, promoting resilience against toxic ammonia upon loss of wt p53 function. These wt p53 metabolic changes also promote polyamine biosynthesis and enhances cell proliferation [25]. We observed that depletion of p53R172H significantly increased the levels of L-aspartate, L-glutamine, creatine, phosphocreatine, creatinine, proline, putrescine, spermidine and spermine (Fig. 2C-E), that are related to pro-tumorigenic mechanisms, including alterations in energy production [26] and polyamines biosynthesis [27]. p53R172H -deficient cells display dysregulation of urea cycle pathway. A Heatmap of global metabolic changes following depletion of p53R172H mutant variant. p value <0.05 and a -1.3